Table 2 Basic parameters input to the model and the ranges of the sensitivity analyses. AEs adverse events, PFS progression free survival, PD progressive disease.

From: Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2− advanced or metastatic breast cancer in China

Model input	Base case	Distribution	Low	High	References
Drug costs per cycle ($)
Abemaciclib	670.08	Gamma	536.07	670.08	YAOZH
Ribociclib	628.79	Gamma	503.04	628.79	YAOZH
Palbociclib	509.07	Gamma	407.25	509.07	YAOZH
Follow-up cost	125.60	Gamma	94.20	157.00	²⁹
Best supportive care cost	783.64	Gamma	587.73	979.55	³⁰
End-of-life care cost	1867.62	Gamma	1400.72	2334.53	³¹
Costs of AEs per event
Neutropenia	114.41	Gamma	91.53	137.29	²⁸
Leucopenia	114.41	Gamma	91.53	137.29	²⁸
Diarrhea	44.30	Gamma	35.44	53.16	²⁷
Anemia	138.03	Gamma	110.42	165.64	²⁸
Hepatobiliary toxicity	87.30	Gamma	69.84	104.76	²⁸
Infection	225.24	Gamma	180.19	270.29	Consulting expert
Proportion of patients received subsequent treatment (%)
Abemaciclib	0.762	Beta	0.716	0.808	^15,16
Ribociclib	0.815	Beta	0.766	0.864	^12,14
Palbociclib	0.769	Beta	0.723	0.815	^9,11
Risk of AEs in Palbociclib
Neutropenia	0.696	Beta	0.557	0.835	^9,11
Leucopenia	0.383	Beta	0.306	0.46	^9,11
Infections	0.052	beta	0.042	0.062	^9,11
Anemia	0.043	Beta	0.034	0.052	^9,11
Risk of AEs in Ribociclib		Beta
Neutropenia	0.571	Beta	0.457	0.685	^12,14
Leucopenia	0.155	Beta	0.124	0.186	^12,14
Hepatobiliary toxicity	0.137	Beta	0.11	0.164	^12,14
Infections	0.077	Beta	0.062	0.092	^12,14
Anemia	0.039	Beta	0.031	0.047	^12,14
Risk of AEs in Abemaciclib		Beta
Neutropenia	0.297	Beta	0.238	0.356	^15,16
Leucopenia	0.111	Beta	0.089	0.133	^15,16
Diarrhea	0.145	Beta	0.116	0.174	^15,16
Anemia	0.09	Beta	0.072	0.108	^15,16
Utility
PFS	0.837	Beta	0.753	0.921	^32,33
PD	0.443	Beta	0.399	0.487	³⁴
Disutilities of AEs
Neutropenia	−0.13	Constant	−0.104	−0.156	^35,36
Leucopenia	−0.13	Constant	−0.104	−0.156	^35,36
Diarrhea	−0.103	Constant	−0.077	−0.129	³⁴
Anemia	−0.073	Constant	−0.058	−0.088	^35,36
Infections	−0.15	Constant	−0.12	−0.18	^35,36
Hepatobiliary toxicity	−0.12	Constant	−0.096	−0.144	³⁴
Discount	0.05	Constant	0	0.08

Back to article page

Table 2 Basic parameters input to the model and the ranges of the sensitivity analyses. AEs adverse events, PFS progression free survival, PD progressive disease.

Search

Quick links